<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36068427</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Approaches to Gene Modulation Therapy for ALS.</ArticleTitle><Pagination><StartPage>1159</StartPage><EndPage>1179</EndPage><MedlinePgn>1159-1179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-022-01285-w</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease for which there is currently no robust therapy. Recent progress in understanding ALS disease mechanisms and genetics in combination with innovations in gene modulation strategies creates promising new options for the development of ALS therapies. In recent years, six gene modulation therapies have been tested in ALS patients. These target gain-of-function pathology of the most common ALS genes, SOD1, C9ORF72, FUS, and ATXN2, using adeno-associated virus (AAV)-mediated microRNAs and antisense oligonucleotides (ASOs). Here, we review the latest clinical and preclinical advances in gene modulation approaches for ALS, including gene silencing, gene correction, and gene augmentation. These techniques have the potential to positively impact the direction of future research trials and transform ALS treatments for this grave disease.</AbstractText><CopyrightInformation>&#xa9; 2022. The American Society for Experimental Neurotherapeutics, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meijboom</LastName><ForeName>Katharina E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA. Robert.Brown@umassmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS111990</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adeno-associated virus (AAV)</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Antisense oligonucleotides (ASOs)</Keyword><Keyword MajorTopicYN="N">CRISPR/Cas9</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">MicroRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>6</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36068427</ArticleId><ArticleId IdType="pmc">PMC9587165</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01285-w</ArticleId><ArticleId IdType="pii">10.1007/s13311-022-01285-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Beckers J, Gossye H, Van Damme P. The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD. Mol Neurodegener. 2022;17(1):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8932121</ArticleId><ArticleId IdType="pubmed">35303907</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaepfel BL, Rothstein JD. RNA is a double-edged sword in ALS pathogenesis. Front Cell Neurosci. 2021;19(15):708181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8326408</ArticleId><ArticleId IdType="pubmed">34349625</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E, Salvador-Palmer R, L&#xf3;pez-Blanch R, Jihad-Jebbar A, Vall&#xe9;s SL, Estrela JM. The link between oxidative stress, redox status, bioenergetics and mitochondria in the pathophysiology of ALS. Int J Mol Sci. 2021;22(12):6352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8231819</ArticleId><ArticleId IdType="pubmed">34198557</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol Dis. 2017;105:283&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans CS, Holzbaur ELF. Autophagy and mitophagy in ALS. Neurobiol Dis. 2019;122:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6366665</ArticleId><ArticleId IdType="pubmed">29981842</ArticleId></ArticleIdList></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MTK, Vickers JC. Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2016;275(Pt 1):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci [Internet]. 2019 [cited 2022 Mar 15];13. Available from: https://www.frontiersin.org/article/10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>French PW, Ludowyke R, Guillemin GJ. Fungal neurotoxins and sporadic amyotrophic lateral sclerosis. Neurotox Res. 2019;35(4):969&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">30515715</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R, Chia R, Traynor BJ, Chi&#xf2; A. Unraveling the complex interplay between genes, environment, and climate in ALS. EBioMedicine. 2021;30(75):103795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728044</ArticleId><ArticleId IdType="pubmed">34974309</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Ghasemi M, Brown RH. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 2015;125(6):2548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518693</ArticleId><ArticleId IdType="pubmed">26030230</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Weishaupt JH. Update on amyotrophic lateral sclerosis genetics. Curr Opin Neurol. 2019;32(5):735&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">31335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Lim J, Wang Q, Purtell K, Wu S, Palomo GM, et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2020;16(5):917&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144840</ArticleId><ArticleId IdType="pubmed">31362587</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3(4):242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659356</ArticleId><ArticleId IdType="pubmed">34901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011;17(1):4&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493865</ArticleId><ArticleId IdType="pubmed">20236142</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiner A, Zinman L, Bourque PR. Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics. CMAJ Can Med Assoc J J Assoc Medicale Can. 2020;192(12):E319&#x2013;E320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101182</ArticleId><ArticleId IdType="pubmed">32392516</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard E, Pegat A, Svahn J, Bouhour F, Leblanc P, Millecamps S, et al. Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS center study. Int J Mol Sci. 2020;21(18):6807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554847</ArticleId><ArticleId IdType="pubmed">32948071</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridovich I. Biological effects of the superoxide radical. Arch Biochem Biophys. 1986;247(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">3010872</ArticleId></ArticleIdList></Reference><Reference><Citation>ALSoD [Internet]. [cited 2022 Mar 21]. Available from: https://alsod.ac.uk/output/gene.php/SOD1.
</Citation></Reference><Reference><Citation>Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl Neurodegener. 2015;24(4):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Laing N, Hurse PV, Brown RH. Toxic mutants in Charcot&#x2019;s sclerosis. Nature. 1995;378(6555):342&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477368</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv Biol Regul. 2016;1(60):95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264(5166):1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18(2):327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon RA, Bunton-Stasyshyn RKA, Fisher EMC, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136(8):2342&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Nordstr&#xf6;m U, Tsiakas K, Johannsen J, Volk AE, Bierhals T, et al. Phenotype in an infant with SOD1 homozygous truncating mutation. N Engl J Med. 2019;381(5):486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">31314961</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Elpers C, Reunert J, McCormick ML, Mohr J, Biskup S, et al. SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis. Brain. 2019;142(8):2230&#x2013;2237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6658856</ArticleId><ArticleId IdType="pubmed">31332433</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward C, Brock DJ, Minns RA, Swingler RJ. Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet. 1998;35(2):174&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1051232</ArticleId><ArticleId IdType="pubmed">9556377</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature. 2022;603(7899):124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS genetics: gains, losses, and implications for future therapies. Neuron. 2020;108(5):822&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A, Gurfinkel Y, Polain N, Lamont W, Lyn RS. Molecular mechanisms underlying tdp-43 pathology in cellular and animal models of ALS and FTLD. Int J Mol Sci. 2021;22(9):4705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125728</ArticleId><ArticleId IdType="pubmed">33946763</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita M, Nonaka T, Hirai S, Miwa A, Okado H, Arai T, et al. Distinct pathways leading to TDP-43-induced cellular dysfunctions. Hum Mol Genet. 2014;23(16):4345&#x2013;4356.</Citation><ArticleIdList><ArticleId IdType="pubmed">24698978</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Wils H, Kleinberger G, Joris G, Cuijt I, Ceuterick-de Groote C, et al. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol. 2013;48(1):22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718993</ArticleId><ArticleId IdType="pubmed">23475610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Brunet F, Dupr&#xe9; N, Chrestian N. The occurrence of FUS mutations in pediatric amyotrophic lateral sclerosis: a case report and review of the literature. J Child Neurol. 2020;35(8):556&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">32281455</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Trends in understanding the pathological roles of TDP-43 and FUS proteins. In: Ghetti B, Buratti E, Boeve B, Rademakers R, editors. Frontotemporal Dementias&#x202f;: Emerging Milestones of the 21st Century [Internet]. Cham: Springer International Publishing; 2021 [cited 2022 Mar 27]. p. 243&#x2013;67. (Adv Exp Med Biol). Available from: 10.1007/978-3-030-51140-1_15.</Citation><ArticleIdList><ArticleId IdType="pubmed">33433879</ArticleId></ArticleIdList></Reference><Reference><Citation>ALSoD [Internet]. [cited 2022 Mar 26]. Available from: https://alsod.ac.uk/output/gene.php/FUS.</Citation></Reference><Reference><Citation>Tyzack GE, Luisier R, Taha DM, Neeves J, Modic M, Mitchell JS, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142(9):2572&#x2013;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Notaro A, Messina A, La Bella V. A deletion of the nuclear localization signal domain in the Fus protein induces stable post-stress cytoplasmic inclusions in SH-SY5Y cells. Front Neurosci [Internet]. 2021 [cited 2022 Mar 27];15. Available from: https://www.frontiersin.org/article/10.3389/fnins.2021.759659.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.759659</ArticleId><ArticleId IdType="pmc">PMC8733393</ArticleId><ArticleId IdType="pubmed">35002600</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, Sendscheid O, El Oussini H, Jambeau M, Sun Y, Mersmann S, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35(10):1077&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868956</ArticleId><ArticleId IdType="pubmed">26951610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S, Sobue G. Importance of functional loss of FUS in FTLD/ALS. Front Mol Biosci. 2018;3(5):44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943504</ArticleId><ArticleId IdType="pubmed">29774215</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IRR, Boeve BFF, Boxer ALL, Baker M, Rutherford NJJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EGPP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney E, Hornberger M, Irish M, Mioshi E, Burrell J, Tan R, et al. Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. JAMA Neurol. 2014;71(3):331&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445580</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Vol. 44, Current Opinion in Genetics and Development. Elsevier Ltd; 2017. p. 117&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Al Khleifat A, Jones AR, Sproviero W, Shatunov A, Opie-Martin S, et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol Commun. 2019;7(1):115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Ferguson SM. C9orf72: at the intersection of lysosome cell biology and neurodegenerative disease. Vol. 18, Traffic. Blackwell Munksgaard; 2017. p. 267&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389918</ArticleId><ArticleId IdType="pubmed">28266105</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Jiang J, Gendron TF, McAlonis-Downes M, Jiang L, Taylor A, et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat Neurosci. 2020;23(5):615&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol (Berl) 2013;126(6):845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJJ, Jansen-West K, Ash PEAA, Caulfield T, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol (Berl) 2013;126(6):829&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339(6125):1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci. 2013;110(51):E4968&#x2013;E4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, Bieniek KF, Gendron TF, Caulfield T, Lin WL, DeJesus-Hernandez M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77(4):639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol (Berl) 2014;128(4):485&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84(6):1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Eshov A, Zhou J, Isiktas AU, Guo JU. C9orf72 arginine-rich dipeptide repeats inhibit UPF1-mediated RNA decay via translational repression. Nat Commun. 2020;11(1):3354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7335171</ArticleId><ArticleId IdType="pubmed">32620797</ArticleId></ArticleIdList></Reference><Reference><Citation>West RJH, Sharpe JL, Voelzmann A, Munro AL, Hahn I, Baines RA, et al. Co-expression of C9orf72 related dipeptide-repeats over 1000 repeat units reveals age- and combination-specific phenotypic profiles in Drosophila. Acta Neuropathol Commun. 2020;8(1):158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487709</ArticleId><ArticleId IdType="pubmed">32894207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science. 2019;363(6428).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Ebbert MTW, O&#x2019;Raw AD, Yue M, Jansen-West K, et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat Med. 2018;24(8):1136&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Belikova AM, Zarytova VF, Grineva NI. Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett. 1967;37:3557&#x2013;3562.</Citation><ArticleIdList><ArticleId IdType="pubmed">6073336</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorati JM, Liu S, Liu A, Gogate A, Nair S, Bahal R, et al. Absorption, distribution, metabolism, and excretion of FDA-approved antisense oligonucleotide drugs. Drug Metab Dispos [Internet]. 2022 Jan 1 [cited 2022 Mar 21]; Available from: https://dmd.aspetjournals.org/content/early/2022/02/27/dmd.121.000417.</Citation><ArticleIdList><ArticleId IdType="pubmed">35221287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;27(70):307&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">30691367</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Bristol LA, Hosler B, Brown RH, Kuncl RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A. 1994;91(10):4155&#x2013;4159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43743</ArticleId><ArticleId IdType="pubmed">7910402</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, Shelanski ML. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci U S A. 1994;91(14):6384&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44206</ArticleId><ArticleId IdType="pubmed">8022792</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116(8):2290&#x2013;2296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558&#x2013;3567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M. Results from the Phase 3 VALOR study and its open-label extension: evaluating the clinical efficacy and safety of tofersen in adults with ALS and confirmed SOD1 mutation [Internet]. Published online October 19, 2021. Available from: https://biogen.gcs-web.com/static-files/b2154d4e-f69f-49d4-9a61-e834387293ea. Accessed 1 Apr 2022.</Citation></Reference><Reference><Citation>Biogen announces topline results from the tofersen phase 3 Study and its open-label extension in SOD1-ALS | Biogen [Internet]. Published online October 17, 2021. Available from: https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-tofersen-phase-3-study-and-its. Accessed 2 April 2022.</Citation></Reference><Reference><Citation>Biogen. A phase 3 randomized, placebo-controlled trial with a longitudinal natural history run-in and open-label extension to evaluate BIIB067 initiated in clinically presymptomatic adults with a confirmed superoxide dismutase 1 mutation [Internet]. clinicaltrials.gov; 2022 Mar [cited 2022 Mar 31]. Report No.: NCT04856982. Available from: https://clinicaltrials.gov/ct2/show/NCT04856982.</Citation></Reference><Reference><Citation>Sareen D, O&#x2019;Rourke JG, Meera P, Muhammad AKMG, Grant S, Simpkinson M, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5(208):208ra149&#x2013;208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Heusler AR, Mistry NA, Vidensky S, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Muhammad AKMG, Gendron TF, Kim KJ, Austin A, et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron. 2015;88(5):892&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110(47).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90(3):535&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN, Wu Y, Odeh HM, Gendron TF, Jansen-West K, del Rosso G, et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med. 2020;12(559):eabb3774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Dodart JC, Tran H, Berkovitch S, Braun M, Byrne M, et al. Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat Commun. 2021;8(12):847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870851</ArticleId><ArticleId IdType="pubmed">33558503</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki Y, Manzano R, Lee Y, Dafinca R, Aoki M, Douglas AGL, et al. C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain. 2017;140(4):887&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">28334866</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, Moazami MP, Yang H, McKenna-Yasek D, Douthwright CL, Pinto C, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2022;28(1):117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis | Biogen [Internet]. Published online March 28, 2022. Available from: https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results. Accessed 6 Apr 2022.</Citation></Reference><Reference><Citation>Liu Y, Andreucci A, Iwamoto N, Yin Y, Yang H, Liu F, et al. WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (2302). Neurology [Internet]. 2021 Apr 13 [cited 2022 Apr 7];96(15 Supplement). Available from: https://n.neurology.org/content/96/15_Supplement/2302.</Citation></Reference><Reference><Citation>Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28(1):104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Promising ALS Therapy Moves Closer to Clinic [Internet]. Columbia University Irving Medical Center. Published online January 24, 2022. Available from: https://www.cuimc.columbia.edu/news/promising-als-therapy-moves-closer-clinic. Accessed 9 Apr 2022.</Citation></Reference><Reference><Citation>Ionis Pharmaceuticals, Inc. A phase 1-3 study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of intrathecally administered ION363 in amyotrophic lateral sclerosis patients with fused in sarcoma mutations (FUS-ALS) [Internet]. clinicaltrials.gov; 2022 Mar [cited 2022 Apr 7]. Report No.: NCT04768972. Available from: https://clinicaltrials.gov/ct2/show/NCT04768972.</Citation></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin 2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen. A phase 1 multiple-ascending-dose study to assess the safety, tolerability, and pharmacokinetics of BIIB105 administered intrathecally to adults with amyotrophic lateral sclerosis with or without Poly-CAG expansion in the ataxin-2 gene [Internet]. clinicaltrials.gov; 2022 Jan [cited 2022 Apr 10]. Report No.: NCT04494256. Available from: https://clinicaltrials.gov/ct2/show/NCT04494256.</Citation></Reference><Reference><Citation>Turner BJ, Cheah IK, Macfarlane KJ, Lopes EC, Petratos S, Langford SJ, et al. Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neurochem. 2003;87(3):752&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">14535957</ArticleId></ArticleIdList></Reference><Reference><Citation>Marc G, Leah R, Ofira E, Oded A, Zohar A, Hanna R. Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice. BioMed Res Int. 2013;2013:845345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3881454</ArticleId><ArticleId IdType="pubmed">24455732</ArticleId></ArticleIdList></Reference><Reference><Citation>Koval ED, Shaner C, Zhang P, du Maine X, Fischer K, Tay J, et al. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet. 2013;22(20):4127&#x2013;4135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781640</ArticleId><ArticleId IdType="pubmed">23740943</ArticleId></ArticleIdList></Reference><Reference><Citation>Shijo T, Warita H, Suzuki N, Ikeda K, Mitsuzawa S, Akiyama T, et al. Antagonizing bone morphogenetic protein 4 attenuates disease progression in a rat model of amyotrophic lateral sclerosis. Exp Neurol. 2018;1(307):164&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">29932880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Cooper-Knock J, Weimer AK, Shi M, Moll T, Marshall JNG, et al. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron. 2022;110(6):992&#x2013;1008.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017397</ArticleId><ArticleId IdType="pubmed">35045337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok A, Raulf N, Habib N. Developing small activating RNA as a therapeutic: current challenges and promises. Ther Deliv. 2019;10(3):151&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30909853</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Jiang W, Hu Q, Li LC, Dong L, Chen R, et al. Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis. Oncotarget. 2016;7(16):22893&#x2013;22910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008410</ArticleId><ArticleId IdType="pubmed">27014974</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JC, Younger ST, Nguyen NB, Hardy DB, Monia BP, Corey DR, et al. Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol. 2008;15(8):842&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574822</ArticleId><ArticleId IdType="pubmed">18604220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, et al. MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-&#x3b1;, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase i trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(15):3936&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pubmed">32357963</ArticleId></ArticleIdList></Reference><Reference><Citation>Fimiani C, Goina E, Su Q, Gao G, Mallamaci A. RNA activation of haploinsufficient Foxg1 gene in murine neocortex. Sci Rep. 2016;20(6):39311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5172352</ArticleId><ArticleId IdType="pubmed">27995975</ArticleId></ArticleIdList></Reference><Reference><Citation>Monian P, Shivalila C, Lu G, Shimizu M, Boulay D, Bussow K, et al. Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides. Nat Biotechnol. 2022;7:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">35256816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Yamashita T, Aizawa H, Tsuji S, Kakita A, Takahashi H, et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012;45(3):1121&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">22226999</ArticleId></ArticleIdList></Reference><Reference><Citation>ALSoD [Internet]. [cited 2022 Apr 25]. Available from: https://alsod.ac.uk/output/gene.php/TARDBP.</Citation></Reference><Reference><Citation>Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A. 1966;55(6):1467&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC224346</ArticleId><ArticleId IdType="pubmed">5227666</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927556</ArticleId><ArticleId IdType="pubmed">30710128</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh NL, Berguig GY, Karim OA, Cortesio CL, De Angelis R, Khan AA, et al. Comprehensive characterization and quantification of adeno associated vectors by size exclusion chromatography and multi angle light scattering. Sci Rep. 2021;11(1):3012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862616</ArticleId><ArticleId IdType="pubmed">33542328</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996;7(17):2101&#x2013;2112.</Citation><ArticleIdList><ArticleId IdType="pubmed">8934224</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther. 2008;15(11):817&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">18401436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun. 2019;10(1):4439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769011</ArticleId><ArticleId IdType="pubmed">31570731</ArticleId></ArticleIdList></Reference><Reference><Citation>Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A. 1993;90(22):10613&#x2013;10617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47827</ArticleId><ArticleId IdType="pubmed">7504271</ArticleId></ArticleIdList></Reference><Reference><Citation>Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease.&#xa0;Johns Hopkins Children&#x2019;s Center, Baltimore, Maryland. Hum Gene Ther. 1996 Jun 10;7(9):1145&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773517</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895694</ArticleId><ArticleId IdType="pubmed">19098898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanguy Y, Biferi MG, Besse A, Astord S, Cohen-Tannoudji M, Marais T, et al. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci. 2015;28(8):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516891</ArticleId><ArticleId IdType="pubmed">26283910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21(12):2148&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR, et al. Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol Ther Nucleic Acids. 2018;3(12):75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Gowing G, Latter J, Chen M, Vit JP, Staggenborg K, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci Off J Soc Neurosci. 2014;34(47):15587&#x2013;15600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Cardozo B, Metterville JP, Toro Cabreja GC, Song L, et al. Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1G93A mice and nonhuman primates. Hum Gene Ther. 2016;27(1):19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79(4):687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018;10(465).</Citation><ArticleIdList><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med. 2020;383(2):151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23(3):668&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888258</ArticleId><ArticleId IdType="pubmed">24108104</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeler AM, Zieger M, Semple C, Pucci L, Veinbachs A, Brown RH, et al. Intralingual and intrapleural AAV gene therapy prolongs survival in a SOD1 ALS mouse model. Mol Ther Methods Clin Dev. 2019;24(17):246&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6962641</ArticleId><ArticleId IdType="pubmed">31970202</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi MG, Cohen-Tannoudji M, Cappelletto A, Giroux B, Roda M, Astord S, et al. A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model. Mol Ther. 2017;25(9):2038&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W, Guo M, Yi L, Liu Y, Li Z, Ma Y, et al. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2020;27(3&#x2013;4):157&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">31819203</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3(12):eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Yi F, Fu L, Yang J, Wang S, Wang Z, et al. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. Protein Cell. 2017;8(5):365&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413600</ArticleId><ArticleId IdType="pubmed">28401346</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Kriz J, Gravel M, Soucy G, Bareil C, Gravel C, et al. Adeno-associated virus&#x2013;mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther. 2014;22(3):498&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944333</ArticleId><ArticleId IdType="pubmed">24394188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadge GD, Pavlovic JD, Koduvayur SP, Kay BK, Roos RP. Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1. Neurobiol Dis. 2013;1(56):74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725968</ArticleId><ArticleId IdType="pubmed">23607939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadge GD, Kay BK, Drigotas C, Roos RP. Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice. Neurobiol Dis. 2019;1(121):131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">30176351</ArticleId></ArticleIdList></Reference><Reference><Citation>Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation [Internet]. Les Turner ALS Foundation. Published online November 30, 2020. Available from: https://lesturnerals.org/oav301-program-for-familial-als-caused-by-sod1-mutation-statement-from-novartis-gene-therapies/. Accessed 19 Apr 2022.</Citation></Reference><Reference><Citation>By. Apic Bio Receives FDA Fast Track Designation for APB-102 | Apic Bio [Internet]. Published online July 28, 2021. Available from: https://apic-bio.com/apic-bio-receives-fda-fast-track-designation-for-apb-102-for-the-treatment-of-patients-with-sod1-als/. Accessed 20 Apr 2022.</Citation></Reference><Reference><Citation>Lim CKW, Gapinske M, Brooks AK, Woods WS, Powell JE, Zeballos CMA, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020;28(4):1177&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, Thammisetty SS, Codron P, Rahimian R, Plourde KV, Soucy G, et al. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J Clin Invest. 2019;129(4):1581&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, et al. Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol Ther Nucleic Acids. 2019;1(14):593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Garc&#xed;a-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, et al. Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol Ther Nucleic Acids. 2019;11(16):26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610329</ArticleId><ArticleId IdType="pubmed">19239892</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Guo S, Bardhi O, Ryskamp DA, Li J, Khoramian Tusi S, et al. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci U S A. 2020;117(31):18591&#x2013;18599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414156</ArticleId><ArticleId IdType="pubmed">32690681</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao X, Meng D, Zhang X, Song Q, Lv H, Jia Y. Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo. Sci Rep. 2022;12(1):5672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983752</ArticleId><ArticleId IdType="pubmed">35383205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouel F, Rolland AS, Devedjian JC, Burnouf T, Devos D. Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates. Front Neurol. 2019;2(10):835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688198</ArticleId><ArticleId IdType="pubmed">31428042</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Pitzer C, Schneider A. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci. 2010;11(4):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902233</ArticleId><ArticleId IdType="pubmed">20592948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Haidet AM, Yang W, Passini MA, Hester M, Clarke J, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther J Am Soc Gene Ther. 2008;16(6):1056&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737251</ArticleId><ArticleId IdType="pubmed">18388910</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Treleaven CM, Fidler JA, Hester M, Haidet A, Handy C, et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther. 2010;18(12):2075&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997594</ArticleId><ArticleId IdType="pubmed">20859261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Hu H, Duan W, Liu Y, Tan G, Li Z, et al. Intramuscular delivery of scAAV9-hIGF1 prolongs survival in the hSOD1G93A ALS mouse model via upregulation of D-amino acid oxidase. Mol Neurobiol. 2018;55(1):682&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">27995572</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wen D, Duan W, Yin J, Cui C, Wang Y, et al. Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway. Brain Res Bull. 2018;1(139):203&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">29499331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LJ, Lu YY, Muramatsu SI, Ikeguchi K, Fujimoto KI, Okada T, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci Off J Soc Neurosci. 2002;22(16):6920&#x2013;6928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757879</ArticleId><ArticleId IdType="pubmed">12177190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Alkaslasi M, Vit JP, Lawless G, Godoy M, Gowing G, et al. Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects. Gene Ther. 2017;24(4):245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404206</ArticleId><ArticleId IdType="pubmed">28276446</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero G, Garc&#xed;a-Lareu B, Herrando-Grabulosa M, Verd&#xe9;s S, L&#xf3;pez-Vales R, Pag&#xe8;s G, et al. Specific expression of glial-derived neurotrophic factor in muscles as gene therapy strategy for amyotrophic lateral sclerosis. Neurotherapeutics. 2021;18(2):1113&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423878</ArticleId><ArticleId IdType="pubmed">33786805</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Pitzer C, Dittgen T, Klugmann M, Dupuis L, Schneider A. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol Ther. 2011;19(2):284&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034860</ArticleId><ArticleId IdType="pubmed">21139572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Kim S, Lee N, Lee J, Yu SS, Kim JH, et al. Intrathecal delivery of recombinant AAV1 encoding hepatocyte growth factor improves motor functions and protects neuromuscular system in the nerve crush and SOD1-G93A transgenic mouse models. Acta Neuropathol Commun. 2019;12(7):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563368</ArticleId><ArticleId IdType="pubmed">31189468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Lee N, Kim S, Lee J, Choi W, Yu SS, et al. Intramuscular delivery of HGF-expressing recombinant AAV improves muscle integrity and alleviates neurological symptoms in the nerve crush and SOD1-G93A transgenic mouse models. Biochem Biophys Res Commun. 2019;517(3):452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">31376938</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton-Jaimes MF, Kahn J, Israelson A. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS. Proc Natl Acad Sci U S A. 2019;116(29):14755&#x2013;14760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642395</ArticleId><ArticleId IdType="pubmed">31262807</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung YT, Peng KC, Chen YC, Yen YP, Chang M, Thams S, et al. Mir-17&#x223c;92 confers motor neuron subtype differential resistance to ALS-associated degeneration. Cell Stem Cell. 2019;25(2):193&#x2013;209.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31155482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mort M, Ivanov D, Cooper DN, Chuzhanova NA. A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat. 2008;29(8):1037&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">18454449</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter JJ, Heil CS, Lueck JD. Therapeutic promise of engineered nonsense suppressor tRNAs. Wiley Interdiscip Rev RNA. 2021;12(4):e1641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8244042</ArticleId><ArticleId IdType="pubmed">33567469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang Y, Mendonca CA, Yukselen O, Muneeruddin K, Ren L, et al. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature. 2022;604(7905):343&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9446716</ArticleId><ArticleId IdType="pubmed">35322228</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkzaban B, Kawalerski R, Coller J. Development of a tethered mRNA amplifier to increase protein expression. Biotechnol J. 2022:2200214.</Citation><ArticleIdList><ArticleId IdType="pubmed">35785475</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, M&#xfc;ller K, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahsen BF, Gray E, Thompson AG, Ansorge O, Anthony DC, Cowley SA, et al. Non-neuronal cells in amyotrophic lateral sclerosis &#x2014; from pathogenesis to biomarkers. Nat Rev Neurol. 2021;17(6):333&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">33927394</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chi&#xf2; A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehky T, Grunseich C. Juvenile amyotrophic lateral sclerosis: a review. Genes. 2021;12(12):1935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8701111</ArticleId><ArticleId IdType="pubmed">34946884</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Nilsson P, Ala-Hurula V, Ker&#xe4;nen ML, Tarvainen I, Haltia T, et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet. 1995;10(1):61&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">7647793</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;15(417):117054.</Citation><ArticleIdList><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler J, Picchiarelli G, Dupuis L, Gonzalez De Aguilar J. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol. 2016;26(2):227&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, Wang JC. Non-viral vectors for RNA delivery. J Control Release Off J Control Release Soc. 2022;342:241&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743282</ArticleId><ArticleId IdType="pubmed">35016918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN, et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci. 2016;113(39):10962&#x2013;10967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047168</ArticleId><ArticleId IdType="pubmed">27621445</ArticleId></ArticleIdList></Reference><Reference><Citation>Flotte TR, Cataltepe O, Puri A, Batista AR, Moser R, McKenna-Yasek D, et al. AAV gene therapy for Tay-Sachs disease. Nat Med. 2022;28(2):251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">35145305</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28(3):709&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054714</ArticleId><ArticleId IdType="pubmed">31968213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29(3):285&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865262</ArticleId><ArticleId IdType="pubmed">29378426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25(3):427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6455975</ArticleId><ArticleId IdType="pubmed">30778238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Efficient delivery of genome-editing proteins in vitro and in vivo. Nat Biotechnol. 2015;33(1):73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289409</ArticleId><ArticleId IdType="pubmed">25357182</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, et al. Nanoparticle delivery of CRISPR/Cas9 for genome editing. Front Genet [Internet]. 2021 [cited 2022 Apr 26];12. Available from: https://www.frontiersin.org/article/10.3389/fgene.2021.673286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.673286</ArticleId><ArticleId IdType="pmc">PMC8149999</ArticleId><ArticleId IdType="pubmed">34054927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Tang Q, Gruntman A, Blomenkamp K, Teckman J, Song L, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther J Am Soc Gene Ther. 2012;20(3):590&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293602</ArticleId><ArticleId IdType="pubmed">22252449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wave Life Sciences Ltd. A multicenter, randomized, double-blind, placebo-controlled, phase 1b/2a study of WVE-004 administered intrathecally to patients with C9orf72-associated amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) [Internet]. clinicaltrials.gov; 2022 Mar [cited 2022 May 2]. Report No.: NCT04931862. Available from: https://clinicaltrials.gov/ct2/show/NCT04931862.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>